^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    SureSeq™ Myeloid Fusion Panel

    Company:
    Sysmex Corp
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The RNA-based SureSeq Myeloid Fusion Panel has been designed in collaboration with leading myeloid cancer experts and has been informed by the latest WHO guidance to include clinically relevant fusions in AML. The panel further enables the identification of gene expression changes in MECOM, supporting the identification of GATA2-MECOM (inv(3)(q21.3q26.2) and RPN1-MECOM (inv(3)(q21q26).
    Cancer:
    Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
    Gene:
    GATA2 (GATA Binding Protein 2), KMT2A (Lysine Methyltransferase 2A), MECOM (MDS1 And EVI1 Complex Locus)
    Method:
    Next-Generation Sequencing (NGS)